Cure8 news brief
A newly FDA-approved biologic (guselkumab/Tremfya) offers another treatment option for adults with moderate to severe Crohn’s disease, including both IV and SC induction choices. This could matter for patients who have not responded to or tolerated other therapies.
Adults with Crohn’s disease, patients currently on or considering biologics, gastroenterologists, and clinical researchers following IBD drug development.
The FDA approved Tremfya (guselkumab) for adults with moderately to severely active Crohn’s disease, adding both subcutaneous and intravenous induction options.
Approval was supported by multiple Phase III trials (including the GRAVITI and GALAXI programmes) involving more than 1,300 participants and pooled analyses that reportedly showed superiority versus ustekinumab (Stelara) on certain endoscopic endpoints.
Tremfya is already approved for ulcerative colitis; this decision represents a new Crohn’s disease indication and gives clinicians and patients an additional biologic option with flexible induction routes. The article emphasizes trial endoscopic and clinical endpoints but does not provide detailed efficacy or safety statistics in the text.
If you are considering treatment changes, discuss with your gastroenterologist whether guselkumab could be appropriate given your disease history, prior therapies, and safety considerations. This approval is a regulatory update rather than treatment guidance.
This is a regulatory approval based on Phase III trials; the article summarizes trial programmes and pooled analyses but does not list detailed efficacy or safety data. It does not replace clinical advice. Pooled superiority versus ustekinumab is reported here but readers should consult full trial publications or regulatory documents for detailed results and safety information.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.
A CHMP recommendation is a major regulatory step toward EU approval — that could mean a new biologic option (guselkumab/Tremfya) for adults with moderate–severe Crohn’s disease, including people who haven’t responded to...
